INTRODUCTION
Cytogenetic aberrations are the most important prognostic parameter in AML 1 . During the last years it became clear that gene mutations add important information to the cytogenetic subtypes. AML with normal karyotype can be genetically further characterized by mutations in FLT3 in terms of internal tandem duplications (FLT3-ITD) 2 or tyrosine kinase mutations (FLT3-TKD) 3;4 as well as by partial tandem duplication in the MLL gene (MLL-PTD) [5] [6] [7] , NPM1 mutations [8] [9] [10] [11] , and CEBPA mutations [12] [13] [14] . The prognostic impact of these mutations was established. NPM1 is regarded as favorable as long as not associated with FLT3-ITD [9] [10] [11] . In addition, gene mutations can be associated with certain cytogenetic aberrations and impact on their primary prognostic significance. Thus, core binding factor leukemias (RUNX1-RUNX1T1 and CBFB-MYH11 positive AML) are associated with a favorable prognosis unless coinciding with KIT mutations which results in a very unfavorable prognosis 15;16 .
A further candidate for prognostic impact in AML is RUNX1. The RUNX1 gene, located at chromosomal band 21q22, is crucial for the process of definite hematopoiesis and the generation of hematopoietic stem cells in the embryo as shown in a mouse model 17 .It contains a "Runt homology domain" (RHD) which is responsible for heterodimerization with the core-binding factor β (CBFβ or PEBP2β) to form a transcription factor and for DNA binding 18 . The second important part of the RUNX1 protein is the transactivation domain followed by a 5 amino acid sequence, VWRPY that is 100% conserved at the C-terminal end of the gene products. RUNX1 can act as activator or repressor of target gene expression depending upon the large number of interacting transcription factors, coactivators and corepressors. RUNX1 acts as a key regulator of hematopoiesis through the regulation of various hematopoietic genes, including growth factors (GM-CSF, MPO, IL3), surface receptors (TCRA, TCRB, M-CSF receptor, FLT3), signaling molecules (CDKN1A, BLK, BCL2), and transcription activators (STAT3, MYB). Thus, RUNX1-regulated target genes are essential for definite hematopoiesis of all lineages 18;19 .
For personal use only. on October 3, 2017 . by guest www.bloodjournal.org From Three classes of acquired alterations of the RUNX1 gene have been discovered in AML: intrageneic mutations, amplification and translocations. Intrageneic mutations have been described mainly for AML M0 20;21 , MDS and AML following MDS 22 as well as for therapyrelated MDS and AML 23 . In addition, RUNX1 mutations have been associated with certain chromosome aberrations. In therapy-related MDS an association with monosomy 7 and rapid progression to AML has been shown 23 . Furthermore, RUNX1 mutations have been shown to be frequently associated with trisomy 21 20 and trisomy 13 24 . Overall RUNX1 mutations have been described mainly in chemotherapy-related MDS, MDS of atomic bomb survivors or in de novo MDS 23;25-27 , and recently also in CMML 28 . Reports about RUNX1 mutations in de novo AML are rare and mostly were focussed on the M0 subtype 20;21 .
The aim of the present study was to analyze the incidence and relevance of RUNX1 mutations in de novo AML. As RUNX1 mutations were found to be mutually exclusive of recurrent fusion genes and also of AML with complex aberrant karyotype 24;29 ) we selected 449 patients with AML and normal karyotype or non complex chromosomal imbalances.
32.7% of this AML cohort was found to carry RUNX1 mutations. As RUNX1 mutations have been described not to be able per se to cause full blown leukemia 30 we also focussed on the analysis of further genetic changes (NPM1, FLT3-ITD, FLT3-TKD, CEBPA, NRAS) and found that MLL-PTD is the most frequent additional aberration in RUNX1 mutated AML followed by FLT3-ITD. A strong prognostically adverse impact of RUNX1 mutations independent of other molecular mutations and other prognostically relevant factors was detected.
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Molecular analysis
Isolation of mononucleated bone marrow (n=404) or peripheral blood (n=45) cells, mRNA extraction, and random primed cDNA synthesis was performed as described previously 2 .
The entire coding region of the RUNX1 isoform AML1b (GenBank entry D43968) was amplified from cDNA using four separate polymerase chain reactions (PCR) and analyzed by 
Cytomorphology, Cytogenetics, Immunophenotyping
Cytomorphologic assessment were done according to the criteria defined in the FAB and the WHO classification 31;32 . Cytogenetic studies were performed after short-term culture.
Karyotypes, analyzed after G-banding, were described according to the International System for Human Cytogenetic Nomenclature 36 . Immunophenotyping was performed as described previously 37 . All analyses were performed in the MLL Munich Leukemia Laboratory.
Statistical analysis
Survival curves were calculated for overall survival (OS) and event free survival (EFS) according to Kaplan-Meier and compared using the two sided log rank test. OS was the time from diagnosis to death or last follow-up. EFS was defined as time from diagnosis to treatment failure, relapse, death, or last follow-up. Relapse was defined according to Cheson et al.
38
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RESULTS

Characterization and distribution of mutations
In total 164 RUNX1 mutations were detected in 147 of these 449 selected patients (32.7%). Two mutations were reproducibly detected by DHPLC but were not further characterizable by sequencing due to small clone size (10-20%). Thus the further characterization refers to 162 mutations. Of the 147 mutated patients 101 (68.7%) revealed a mutation pattern indicating a low allelic mutation burden (mutation/wildtype ratio of 1 or lower) regarded as "heterozygous", in 29 patients (17.9%) no RUNX1 wildtype (wt) was detectable and these cases were subsequently indicated as "LOH cases" (loss of heterozygousity), and 14 (8.6%) had two different heterozygous mutations. Three cases (1.9%) had one mutation with an LOH pattern and had a second mutation with a heterozygous pattern at a region different from the region bearing the LOH type mutation.
According to the mutation load in these three latter cases one case with a 50% and 100% load obviously has a subclone with two mutations in one allele, whereas the other two cases with a 25% and a 75% load, each, most probably had two clones with a different RUNX1 mutation each. Due to methodological reasons in all patients with obvious heterozygousity (low allele burden) cells with LOH at the RUNX1 locus diluted by unmutated cells can not be excluded.
The mutations consisted of 60 (37.0%) missense, 18 (11.1%) nonsense, 72 (44.4 %) frameshift, 9 (5.6%) in frame insertion/deletion mutations as well as one exon 5 and two exon 7 skipping mutations (1.9%). The mutations are distributed throughout the gene as indicated in figure 1 .
Mutations are numbered according to Ensemble cDNA sequence ENSG00000159216 transcript RUNX1-001(ENST00000344691).
According to the position of the mutation within the gene 98 (60.5%) of all mutations were in the RUNT homology domain (RHD), 24 (14.8%) in the transactivation domain (TAD), 26
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From (16.0%) in between these two domains and 13 (8.0%) were found 3´ of the TAD. A single frame shift mutation was detected 5´of the RHD. In the RHD all different kind of mutations were detected, whereas 3´ of the RHD missense mutations were very rare and totally absent in the TAD. Patients with an LOH pattern most frequently revealed mutations in the RHD (29/32; 90.6%) whereas the mutations of heterozygous cases are scattered throughout the gene. Frameshifts are greatly underrepresented in mutations with LOH pattern (3/32; 9.4%) compared to heterozygous mutations (69/118; 58.5%, p<0.001).
In additional 8 cases the L29S amino acid exchange was observed which has been described to be a functional neutral polymorphism 21 . These cases were not regarded to be mutated. Other non-functional polymorphisms that have been described previously, S21syn, G42R, H58N, and I87syn 30 were not observed in our cohort.
A familial history of thrombocytopenia or familial platelet disorders were not known in any of the 147 RUNX1 mutated cases. Remission samples were available in 60 patients (data not shown) and did not reveal a RUNX1 mutation at remission, thus a germline mutation could be excluded in all cases tested in parallel.
Correlation to clinical features
The distribution of RUNX1 mutations according to sex was equal (31.9% in male and 33.8% in females, n.s. 
Distribution of RUNX1 mutations according to cytogenetics
The cohort was selected according to cytogenetics. Only patients with normal karyotype (NK) and non complex chromosomal imbalances were included (table1). The highest frequency of RUNX1 mutations with 90.0% (27/30 cases) was detected in the group with trisomy 13. The frequencies in the groups with NK and single chromosomal losses or gains (-7/del(7q), +8, +11, and +21) were similar ranging from 29% to 36%, respectively (table 1) .
Only few cases with chromosomal deletions mainly del(5q), del(9q) and del(20q) were analyzed (total: n=22), however, if combined to one group they also revealed an overall RUNX1 mutation frequency of 22.8% (5/22 cases) (table 1) .
Cooperating mutations
A further aim of this study was the identification of cooperating mutations in RUNX1 
Stability of the RUNX1 mutations
For 10 patients mutation status and cytogenetics were available at diagnosis and at relapse of AML. One case relapsed with a RUNX1 mutation different from that at diagnosis (p.V103F and 47,XY,+13 at diagnosis and p.N112_Y113insP and NK at relapse) and was subsequently regarded as secondary AML. RUNX1 was stable with the same RUNX1 mutation status at diagnosis and relapse in 9 cases. In contrast, karyotype was stable in only 5 of these cases (NK: n=2, +13: n=1; +21: n=1; del(7q): n=1). One case had a shift from NK to del(12p), one from NK to t(2;12)(q31;p13), one from +8 to +14, and one from +13 to NK.
The case with t(2;12)(q31;p13) lost the MLL-PTD and FLT3-ITD at relapse. The case with del(7q) gained an FLT3-ITD and the case with +21 lost the NRAS mutation at relapse. These data show genetic heterogeneity between diagnosis and relapse with respect to cytogenetic and molecular markers. Solely the RUNX1 mutation was stably retained. Even the RUNX1 status (6 heterozygously mutated, 2 with loss of wildtype, and one with two different mutations) was identical in the diagnostic and relapsed samples. These data indicate that RUNX1 is the underlying initial or at least the first detectable genetic event in these cases.
Prognostic relevance of RUNX1 mutations
Clinical data for the evaluation of prognosis parameters were available from 316 cases 
Impact of different RUNX1 and NPM1 mutation status
Only one case was RUNX1/NPM1 double mutated and thus these two markers are almost exclusive. We performed a survival analysis of the three remaining constellations:
RUNX1wt/NPM1wt (n=136), RUNX1mut/NPM1wt (n=96), and RUNX1wt/NPM1mut (n=47) to exclude that the prognostic adverse impact of RUNX1mut compared to RUNX1wt is due to the positive impact of NPM1 in the RUNX1 unmutated group. As shown in figure 4a RUNX1mut/NPM1wt was worse compared to RUNX1wt/NPM1wt and RUNX1wt/NPM1mut 
Influence of RUNX1 mutation characteristics on outcome
To analyze for possible differences of certain mutation types, first heterozygously RUNX1 mutated AML (n=101) were analyzed in comparison to cases with LOH (n=29) and those with two different mutations (n=17) (including the 3 cases with LOH and two different mutations which are separately displayed in figure 1 ). There were no significant difference in OS and EFS between these three groups. A detailed analysis of the position of the mutations did not show any prognostic relevance either (see supplementary material).
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Prognostic influence of age, karyotype and morphology on prognosis
In addition to other molecular mutations and mutation type the following prognostic factors were analyzed in a univariate analysis: age, gender, white blood cell count (WBC), FAB subtype, CD34 positivity. As summarized in supplementary table 3 an unfavorable impact on OS was shown for higher age (p<0.001), higher WBC (p=0.008), and higher FLT3-ITD/FLT3wt ratio (p=0.031). Surprisingly, females were found to have a better OS (p=0.012) compared to males. An unfavorable impact on EFS was shown for higher age (p<0.001), male gender (p=0.031), higher WBC (p=0.019), and a favorable impact on EFS was shown for NPM1 mutations (p=0.049).
Subsequently all parameters that were significantly associated with prognosis in the univariate Cox regression analysis where further analysed in a multivariate analysis. As shown in supplementary table 4, RUNX1 mutation positivity (p=0.029), a higher FLT3-ITD/wt ratio (p=0.003), high age (p<0.001), and high WBC (p=0.002) came out to be independent adverse prognostic parameters for OS. The proportial hazards assumption was met for all parameters entered into the multivariate analysis.
DISCUSSION
As RUNX1 mutations were shown to be mutually exclusive of recurrent reciprocal translocations and complex aberrant karyotype 29 ;39 , we selected our cohort according to normal karyotype (NK AML) and those with non complex chromosomal imbalances. We detected a considerable frequency of nearly one third of these AML that carried a RUNX1 mutation. This data is supportive of RUNX1 mutations belonging to the most frequent molecular aberrations in de novo AML. However, it has to be considered that our analysis for RUNX1 mutations was restricted to cytogenetically defined subsets of AML.
Our study suggests a higher overall frequency of RUNX1 mutations as compared to previous studies 20;22;23;29 . This may be caused by our selection for normal karyotype and non complex chromosomal imbalanced cases. An additional reason of different mutation frequencies not only of RUNX1 but also of NPM1 most obviously are different age structures
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From in the different studies. The age in the present cohort was clearly higher (median 67.7 years) than in the study of Tang et al (median 52.0 years) 29 and that of Gaidzik (range 16-60 years) 40 . In addition, as described previously, NPM1 mutations occur at higher frequencies in younger patients which is in line with the differences between the present cohort and the above mentioned cohorts. These differences in age also have to be considered the cause for a higher frequency of RUNX1 mutations in the present cohort since Tang Although previous data also showed that RUNX1 is most frequently mutated in AML of the FAB M0 subtype 20;21 , and in those with a trisomy 13 24 we detected an even higher rate in our cohort. This can be explained by the same reasons as mentioned above. Furthermore, the high frequency of 65.2% RUNX1 mutations in M0 in our cohort is in part the result of an additional selection bias, as complex aberrant karyotypes, which are frequent in M0 were not included in this study 41 .
We were able to confirm the higher age of the RUNX1 mutated patients compared to the RUNX1 wildtype cases as recently published 29 . However, the high male prevalence (18.4% vs. 6.4%) as reported in the same study could was not confirmed in our cohort . However, MLL-PTD does not seem to carry out a typical type 1 mutation function responsible for proliferation. As in 17 of the 147 RUNX1 mutated cases (11.6%) at least two further mutations were detected in addition to RUNX1 a more than 2-hit hypothesis may be discussed at least for the RUNX1 mutated AML Cytogenetic and molecular genetic data were available in paired samples from diagnosis and relapse in ten cases and showed stability of RUNX1 in 9/10 samples in contrast to instability of other markers like FLT3, NRAS and cytogenetic aberrations. One additional patient developed secondary AML with a different type of RUNX1 mutation as compared to primary AML. These data suggest that RUNX1 is the initiating event or at least the earliest detectable event, so far, in RUNX1 mutated AML. In analogy to NPM1 and CEBPA 32;50 , RUNX1 mutated AML may therefore be suggested to be a specific AML entity. This is further supported by the clinical data as the effect of RUNX1 on outcome is impressive. For OS and EFS a highly significant unfavorable effect of RUNX1 could be shown in the total group, in NK, and also if other molecular aberrations were taken into account. Very recently, an unfavorable outcome of RUNX1 mutated de novo AML also has been shown 29 . Our study supports these data. Furthermore, data on the correlation of RUNX1 mutations to other molecular mutations showed that FLT3-ITD 2 and the MLL-PTD 5 did not confer an additional unfavorable impact on the RUNX1mut status and vice versa.
In conclusion, these data clearly show that RUNX1 is frequently mutated in de novo AML with normal karyotype or non complex chromosomal imbalances. It can be detected especially in cases that lack other aberrations as defined by the WHO classification and that represent certain biological subgroups (e.g.
PML-RARA, RUNX1-RUNX1T1, CBFB-MYH11)
or provisional entities like NPM1 or CEBPA mutated AML. As RUNX1 mutations have a strong adverse prognostic effect in AML with NK or non complex chromosomal imbalances especially in those that do not carry CEBPA, NPM1, FLT3-ITD or MLL-PTD it is strongly suggested to be implemented into the diagnostic workup of AML. Furthermore, it is suggested as a new candidate molecular marker along with NPM1/FLT3-ITD and CEBPA mutations, to stratify patients for treatment. However, in the current study patient were treated very heterogeneously, thus the optimum therapy for patients with RUNX1 mutations should be defined in randomized therapeutic trials. This also may have implications for follow up studies and therapy monitoring.
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